Plain-English translation of NCT06976190 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase III clinical trial testing whether MRG003 combined with pucotenlimab works better than traditional chemotherapy for people with nasopharyngeal cancer that has returned or spread to other parts of the body after their initial treatment. About 446 people will participate across multiple hospitals. You would be randomly assigned to receive either the new two-drug combination or standard chemotherapy, and researchers will carefully track how well the treatment works and what side effects occur.
Nasopharyngeal cancer that returns or spreads is very difficult to treat, and standard chemotherapy has limited effectiveness. This trial exists to see if this new medication combination can help these patients live longer and with fewer serious side effects than current standard treatments.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to receive either the new two-drug combination or standard chemotherapy. You'll visit the hospital regularly for treatment sessions and blood tests to monitor how well the treatment is working and to watch for side effects. The study team will carefully measure your tumors on scans and track your health throughout the trial to compare how effective and safe each treatment is.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China